An ongoing dialogue on HIV/AIDS, infectious diseases,
March 3rd, 2010
Ritonavir Tablets: Any Experience Out There Yet?
Ritonavir tablets have been approved, and are apparently now in pharmacies. The capsules will also remain available for the foreseeable future.
However, I haven’t switched anyone over from the capsules yet, and neither has anyone else in our practice.
Would be interested in hearing how it’s going so far — best news would be that the tablets are both more convenient and have fewer side effects, but we know from the switch to Kaletra tablets that the latter might not occur.
(Which surprised me, I have to admit — thought the tablets would be better tolerated, but it was about the same.)
So … if you’ve switched patients to from the capsules to the tablets, comment away!
Categories: HIV, Patient Care
Tags: antiretroviral therapy, HIV, ritonavir
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
2 Responses to “Ritonavir Tablets: Any Experience Out There Yet?”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
Sorry. No data so far.
-
From the Blog — Most Recent Articles
- Farewell to This Blog — and Hello to NEJM Voices March 2, 2026
- Some Ruminations on CROI — Still the Best HIV Meeting February 26, 2026
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing February 17, 2026
- Sometimes You Just Need to Get Input from a Real Human Being February 12, 2026
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
FROM NEJM — Recent Infectious Disease Articles- Andes Hantavirus Outbreak on a Cruise Ship, 2026 June 25, 2026On May 2, hantavirus infection was diagnosed in a patient who had been on a cruise ship. Subsequent evaluation revealed multiple cases of Andes hantavirus infection on the ship. To date, three associated deaths have occurred.
- Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection June 25, 2026In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo.
- Clusters of Concern — Spatial Link between Childhood Undervaccination and Measles Outbreaks in South Carolina June 25, 2026Spatial analysis in South Carolina revealed that measles infections were clustered in areas where public school vaccination rates were lower.
- Improving Global Air-Quality Indices — The WHO’s New Roadmap June 25, 2026Many countries rely on air-quality indices to inform the public and help protect people during short-term increases in air pollution. Their use has important societal and economic implications.
- A Major Step toward a Cure for Hepatitis B Infection June 25, 2026The current treatment of chronic hepatitis B infection includes nucleoside or nucleotide analogue (NA) therapy and pegylated interferon. Both of these treatments are effective in suppressing hepatitis B virus (HBV) replication and in reducing the risk of cirrhosis and hepatocellular carcinoma.1 However, these treatments do not eradicate HBV,...
- Andes Hantavirus Outbreak on a Cruise Ship, 2026 June 25, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

We have been using generic RTV tablet since 2-3 years in India and all the capsules have been withdrawn since then. The tolerance is good
Sanjay, thanks for the comment. I wonder how your generic ritonavir compares with the version now licensed in the USA.